TBC1D16 Activators

Forskolin, a diterpene, acts by raising intracellular cAMP levels, which activate protein kinase A and may indirectly modulate TBC1D16 through phosphorylation events. The macrolide rapamycin, in contrast, is a selective mTOR inhibitor, exerting its effect on the intricate mTOR signaling pathways, which could impact TBC1D16's role in cellular metabolism and growth processes. Small molecule inhibitors such as Y-27632 and SB203580 target the Rho-associated protein kinase and p38 MAP kinase, respectively, altering the cytoskeletal dynamics and stress response pathways, which may in turn affect TBC1D16's trafficking-related functions.

U0126 and PD98059, both of which act as MEK inhibitors, can modify the MAPK/ERK pathway, potentially influencing TBC1D16's activity or expression. LY294002 and Wortmannin, as PI3K inhibitors, impact the AKT signaling pathway, which is integral to membrane trafficking and could thereby influence TBC1D16's role within these cellular processes. Compounds like PP2, an Src family kinase inhibitor, and Go6976, a PKC inhibitor, may modulate signaling cascades, affecting TBC1D16's GAP activity for Rab GTPases or its interactions with other proteins. NSC23766 specifically inhibits Rac1, a small Rho GTPase, which can impact actin cytoskeleton remodeling, possibly influencing TBC1D16's involvement in intracellular transport.